Coronavirus disease 2019 covid-19 hospitalizations and deaths can be prevented in large part by universal vaccination, although there is significant inter-individual variability in the effectiveness of the covid-19 vaccinations, mostly because of recipients' variable immunological responses. As a result, the objective of this opinion piece is to explore several elements of the possibility of monitoring anti-sars-cov-2 antibodies both before and after covid-19 vaccination, highlighting the benefits and drawbacks of this approach. In conclusion, the benefits of testing anti-sars-cov-2 antibodies in people who have received the covid-19 vaccination include determining the baseline seroprevalence of sars-cov-2 infection in people who have not received the vaccine, early detection of low or non-responders to the covid-19 vaccination, and Timely Detection of faster anti-sars-cov-2 antibody level decay. Contrarily, potential drawbacks to date include an unproven equivalence between anti-sars-cov-2 antibody titer, neutralizing activity, and vaccine efficacy; the absence of cost-effective analyses of various testing strategies; and the enormous volume of blood draws and growth in laboratory workload that would be required to support universal anti-sars-cov-2 antibodies testing. Identification of cohorts to be tested first, such as those at higher risk of contracting variations of concern, those at higher risk of illness progression that is not favorable, and individuals in whom vaccination immunogenicity may be anticipated to be lower and/or shorter, is one potential option.
